SCHEMBL857137

SCHEMBL857137

Brc1cnc2c(c1)ncn2C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.36
PTPN7 P35236 3/20 0.36
DUSP3 P51452 2/20 0.36
HSD17B10 Q99714 1/20 0.34
ENPP3 O14638 1/20 0.34
ENPP1 P22413 1/20 0.34
HDAC8 Q9BY41 1/20 0.33
MAOB P27338 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
GABRA2 P47869 1/20 0.32
GABRA6 Q16445 1/20 0.32
HCAR1 Q9BXC0 1/20 0.32
SIRT2 Q8IXJ6 1/20 0.32
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7213819 0.78 GRM5 (0.34) GRM5CYP11B1CYP11B2SIRT2
SCHEMBL3042174 0.77 NPC1 (0.41) GRM5HSD17B10CYP11B1CYP11B2MEN1
SCHEMBL858470 0.76 MET (0.42) HSD17B10HDAC8CYP11B1CYP11B2MEN1
SCHEMBL28083639 0.75 CYP1A2 (0.44) HSD17B10CYP11B1CYP11B2MEN1KMT2A
SCHEMBL7214729 0.74 FGFR1 (0.48) GRM5KMT2AFGFR1KDR
SCHEMBL29447536 0.74 NPC1 (0.39) HSD17B10CYP11B1CYP11B2GABRA1GABRG2
SCHEMBL3037362 0.74 NPC1 (0.39) HSD17B10CYP11B1CYP11B2GABRA1GABRG2
SCHEMBL481960 0.71 HSD17B10 (0.38) GRM5PTPN7DUSP3HSD17B10ENPP3
SCHEMBL30582407 0.71 NR3C1 (0.32) MAOBCYP11B1CYP11B2MEN1KMT2A
SCHEMBL16764670 0.70 CYP11B1 (0.33) CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA GRM5 494/4885PTPN7 2409/4885DUSP3 343/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA GRM5 460/4885PTPN7 2842/4885DUSP3 511/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA GRM5 558/4885PTPN7 2541/4885DUSP3 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.